Nathan Jorgensen

Bio:

Nathan Jorgensen, Ph.D., MBA, is a biotechnology executive and strategic finance leader with experience spanning biotech operations, healthcare investing, equity research, and scientific research. He currently serves as a Growth Partner at Flagship Pioneering, where he brings a multidisciplinary approach to building and scaling innovative life sciences companies. Prior to joining Flagship, Nathan served as Chief Financial Officer of Voyager Therapeutics, where he led significant enhancements to the finance organization, systems, and operational processes, while helping reposition the company during a challenging market environment. Previously, as Chief Financial Officer of Vor Bio, he oversaw finance, investor relations, communications, facilities, GMP operations, and IT, and helped raise more than $400 million through public and private financings. Earlier in his career, Nathan built global public and private healthcare investing capabilities at the Qatar Investment Authority, the sovereign wealth fund of the State of Qatar, and managed pharmaceutical and biotechnology investments at Calamos Investments, a growth-focused investment firm with approximately $30 billion in assets under management. He also worked in biotechnology equity research at Stifel. Before transitioning into finance and operations leadership, Nathan conducted neuroscience research focused on the pathobiology of Parkinson’s disease as a postdoctoral scientist at Columbia University Irving Medical Center. He holds an MBA from Cornell SC Johnson College of Business and a Ph.D. in neuroscience from University of Minnesota.